Imagine testing a drug's effect on human memory and cognition before it ever enters a clinical trial. That's the audacious mission of Axosim, a biotech company quietly engineering human brain models with neurological functions, from memory to learning.

"They aren't just building petri dishes; they're building a new testing ground for the human brain itself."

The biotech landscape is crowded with organ-on-chip startups, but Axosim’s specific focus on *neurological functions*—memory, learning, and cognition—sets them apart. While competitors focus on liver or kidney toxicity, Axosim tackles the most complex organ. The tech stack (jQuery, Tailwind, HubSpot) reveals a pragmatic approach: functional web presence over flashy design, prioritizing investor relations and talent acquisition over consumer traffic.

• The '28bio' branding suggests a dual identity or a specific scientific methodology (possibly 28-day cycles or 28 distinct neural markers).
• Zero reported web traffic is a red flag for brand awareness but a green flag for B2B focus—they sell to pharma giants, not the public.
• The lack of Trustpilot reviews is standard for deep tech; their 'reviews' come from clinical trial data and partner validations.